

Hippo pathway in lung development

Yuyuan Dai, David Jablons, Liang You

Thoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center, University of California, San Francisco, CA, USA

Correspondence to: Liang You. Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California, 2340 Sutter Street, N-221, San Francisco, CA 94115, USA. Email: liang.you@ucsf.edu.

Provenance: This is an invited Editorial commissioned by Section Editor Dr. Chunlin Ou (Cancer Research Institute of Central South University, Changsha, China).

Comment on: Otsubo K, Goto H, Nishio M, *et al.* MOB1-YAP1/TAZ-NKX2.1 axis controls bronchioalveolar cell differentiation, adhesion and tumour formation. *Oncogene* 2017. [Epub ahead of print].

Submitted Mar 24, 2017. Accepted for publication Mar 29, 2017.

doi: 10.21037/jtd.2017.07.18

View this article at: <http://dx.doi.org/10.21037/jtd.2017.07.18>

Lung development stages

The mammalian lung is a highly branched organ for oxygen exchange with carbon dioxide in the cardiovascular system. Multiple signaling pathways, including the Wnt, bone morphogenetic protein (Bmp), and fibroblast growth factor (Fgf) pathways, are implicated in regulating lung specification, branching and patterning (1).

Lung morphogenesis in mice can be divided into five stages: (I) embryonic stage [embryonic day (E) 9.0–12.5]—formation of the lung buds and major bronchi, division of tracheal-esophageal tube; (II) pseudoglandular stage (E12.5–16.5)—proliferation of bronchial branches, acinar tubules and buds, vasculogenesis and innervation; (III) canalicular stage (E16.5–17.5)—organization of the pulmonary vascular bed, pulmonary acinus, and increasing innervation; (IV) saccular stage [E17.5; postnatal (P) 5]—dilation of peripheral airspaces, differentiation of the respiratory epithelium and increasing vascularity of the saccules, surfactant synthesis; (V) alveolarization stage (P5–28)—growth and septation of the alveoli, maturation of the pulmonary vascular system (2).

Hippo pathway introduction

The Hippo pathway was first discovered in *Drosophila* functioning in tissue growth (3). In mammalian cells, the core Hippo pathway is composed of Mst1/2 kinases, which together with Sav1 (also called WW45) and Mob1A/B activate the Lats1/2 kinases to promote Yap and Taz phosphorylation (4). The phosphorylated Yap and Taz are restricted to locate in the cytoplasm and inactivated due to

degradation. The hypo-phosphorylated Yap and Taz are active, which are translocated into the nucleus and bind TEAD transcription factor inducing expression of genes involving in cell proliferation, differentiation and death. All of these molecules have been implicated as tumor suppressors except Yap and Taz. The wide range of genes regulation by Yap/Taz makes the Hippo pathway a critical player in tissue development, regeneration and tumor development. However, whether the Hippo pathway plays a role in key steps of lung development and physiology are underexplored.

Homozygous-null mutant mice lacking *Mst1/2*, *Sav1*, *Lats2*, or *Yap* are all embryonic lethal (Table 1) (5–10). However, *Taz*-null mice showed partial lethality started at the perinatal stage (11). Only 20% of *Taz*-null mice survived at weaning. *Taz*-deficient homozygotes showed multiple renal cysts in the kidney and abnormal alveolarization during lung development mimicking emphysema. The early embryonic lethality of most Hippo components precluded study of these mediators in lung development. Conditional knockout and lung specific knockout of Hippo pathway components in mice would provide a more definitive answer to the role of Hippo signaling in the lung and elucidate the molecular mechanisms by which Hippo signaling controls various aspects of lung biology.

This editorial mainly focuses on the function of the Hippo pathway in lung development.

Mst1/2

The expression of *Mst1/2* in developing lung has not been

Table 1 Phenotypes of homozygous-null Hippo pathway components mutant mice

Gene	Phenotype	References
<i>Mst1/2</i>	Embryonic lethality at E8.5	(5,6)
<i>Sav1</i> (<i>WW45</i>)	Embryonic lethality	(7)
<i>Lats2</i>	Embryonic lethality	(8)
<i>Mob1a/1b</i>	Embryonic lethality at E8	(9)
<i>Yap1</i>	Embryonic lethality at E9.5–10.5	(10)
<i>Taz</i>	Viable, but formed multiple cysts in the kidney and greatly enlarged air space in the lung (resemble human polycystic kidney diseases and pulmonary emphysema respectively)	(11)

Table 2 Mouse model and phenotypes of lung-specific Hippo pathway components knockout mouse

Mouse model	Phenotype	References
<i>YAP^{flf}; Shh^{Cre/+}(Yap^{cnnull})</i>	Lethality at birth, lungs from <i>Yap^{cnnull}</i> were highly hypoplastic and showed sever disruption in branching morphogenesis at E14.5, resulting in dilated cyst-like structures	(14)
<i>Mst1^{flf}; Mst2^{flf}; Shh-Cre</i>	Lethality at birth, while lobation and lung size were generally unaffected, sacculation was inhibited and lung cellularity was increased in E18.5	(13)
<i>Scgb1a1-rtTA/tetO-Cre/Mst1^{flf}; Mst2^{flf}</i>	Deletion of <i>Mst1/2</i> in the postnatal bronchiolar epithelium upon administration of doxycycline induced progressive airway hyperplasia	(13)
<i>Mst1^{-/-}; Mst2^{flf}; Nkx2.1^{Cre/+}</i>	Viable and fertile without apparent gross abnormalities	(15)
<i>Mst1^{-/-}; Mst2^{flf}; Nkx2.1^{Cre/Cre}</i>	Postnatal lethality, most died within 3 weeks after birth	(15)
<i>Mst1^{-/-}; Mst2^{flf}; Shh^{Cre/+}</i>	Neonatal lethality, 95% died soon after birth because of respiratory failure	(15)
<i>Mst1^{-/-}; Mst2^{flf}; Shh^{Cre/Cre}</i>	Embryonic lethality, causing cyclopia, holoprosencephaly and limb and lung defects due to disruption of the <i>Shh</i> locus	(15)
<i>Sav^{flf}; Nkx2.1-Cre</i>	Viable and fertile without apparent gross abnormalities	(12)
<i>Mst1^{flf}; Mst2^{-/-}; Nkx2.1-Cre</i>	Postnatal lethality, all mice died within the first 15 days after birth because of respiratory failure, reduced aerated space compacted with immature-looking cuboidal cells at E18.5 and PN1	(12)
<i>SPC-rtTA/(tetO)₇-Cre/Mob1A^{flf}; Mob1B^{-/-}</i>	Neonatal lethality; ~73% died within 1h of birth. Deletion of <i>Mob1A/1B</i> in the bronchioalveolar epithelium upon administration of doxycycline in utero at E6.5–18.5. Mutant lung at E18.5/PO showed alveolar septal hyperplasia with reduced airspaces	(16)

studied. *Mst1/2*-null mice lacking both *Mst1* and *Mst2* genes begin dying at E8.5 (5,6). Lung specific *Mst1/2* knockout mice (*Mst1^{flf}; Mst2^{-/-}; Nkx2.1-Cre*) die in the perinatal period within the first 15 days after birth and show phenotype mimicking RDS in preterm infants (12). There were no significant differences between the lungs of *Mst1/2*-dKO and wild-type mice until E17.5. However, at E18.5 and P1, alveoli of *Mst1/2*-dKO lungs displayed a greatly reduced aerated space compacted with immature AEC2 cells which fail to produce surfactant proteins normally. Chung *et al.* 2013 demonstrated that *Mst1/2* regulated surfactant protein expression and maturation of

AEC2 through *Foxa2* by phosphorylation and stabilization of *Foxa2* and independently of canonical *Yap/Taz* Hippo signaling pathway (12). The independence of Hippo/*Yap* was supported by decreased *Yap* activity in knockout lungs and knockdown *Yap* level in MLE-12 cells did not affect surfactant protein expression.

However, studies by Lange *et al.* 2015 utilizing conditional knockout mice in lung tissues found *Mst1/2* regulated lung development through conserved Hippo/*Yap* signaling (13). Lange *et al.* 2015 constructed *Mst1^{flf}; Mst2^{flf}; Shh-Cre* mouse model (Table 2) to delete *Mst1* and *Mst2* from respiratory epithelial cell progenitors during lung

formation. The *Mst1/2* ablation caused lung abnormalities and resulted in death at birth. The phenotype of *Mst1^{ff}*; *Mst2^{ff}*; *Sbb-Cre* mice and *Mst1^{ff}*; *Mst2^{-/-}*; *Nkx2.1-Cre* are similar and mimicking RDS. The lung in mutant mice started to show apparent abnormalities until E18.5. Reduction of Surfactant proteins expression and mature AEC2 cells were also detected in lungs of *Mst1^{ff}*; *Mst2^{ff}*; *Sbb-Cre* mice. In contrast to previous study, *Foxa2* expression was unchanged and Yap activity was increased in embryonic lungs of *Mst1^{ff}*; *Mst2^{ff}*; *Sbb-Cre* mice. *Mst1/2* deletion also increased *Ajuba* expression in embryonic lungs. *Ajuba* is a potential regulator of lung epithelial cell proliferation and differentiation through *Mst1/2*-Yap signaling. *Mst1/2*-Yap-*Ajuba* axis was proposed for regulation of respiratory epithelial cell proliferation and differentiation.

Another study by Lin *et al.* 2015 utilizing a different *Mst1/2* conditional knockout mice (*Mst1^{-/-}*; *Mst2^{ff}*; *Sbb^{Cre/+}*) model (Table 2) also demonstrated *Mst1/2* regulated lung growth through canonical Yap/Hippo signaling (15). *Mst1^{-/-}*; *Mst2^{ff}*; *Sbb^{Cre/+}* mice died soon after birth. Lin also carefully compared lung development and phenotypes of different *Mst1/2* deleting mice models (*Mst1^{-/-}*; *Mst2^{ff}*; *Nkx2.1^{Cre/+}* and *Mst1^{-/-}*; *Mst2^{ff}*; *Nkx2.1^{Cre/cre}* and *Mst1^{-/-}*; *Mst2^{ff}*; *Sbb^{Cre/+}*) which had different Cre-activity. *Mst1/2* protein deletion is more complete in which *Mst1/2* are removed by *Sbb-cre* than those induced by *Nkx2.1-Cre*. *Sbb-cre* seems to exhibit a high efficiency to remove *Mst1/2* in the lung epithelium. A severe lung defect causing *Mst1^{-/-}*; *Mst2^{ff}*; *Sbb^{Cre/+}* mice neonatal lethality in contrast to a milder lung defect causing *Mst1^{-/-}*; *Mst2^{ff}*; *Nkx2.1^{Cre/cre}* mice postnatal lethality. A relative elevation of Yap activity was found in *Mst1^{-/-}*; *Mst2^{ff}*; *Sbb^{Cre/+}* embryonic lungs and regulation of surfactant proteins expression by *Mst1/2* through Yap was confirmed *in vitro*. This study suggested a conserved *Mst1/2*-Yap signaling played a role in lung development.

Mob1a/b

Mob1 expression was detected in all stages tested during E14.5 and E18.5 and started to increase at E16.5 (16). *Mob1a/b*-null mice lacking both *Mob1a* and *Mob1b* genes died at E8. Doxycycline (Dox)-inducible, bronchioalveolar epithelium-specific, null mutations of *Mob1a/b* in mice (*SPC-rtTA/(tetO)₇-Cre/Mob1a^{ff}/Mob1b^{-/-}*; termed *luMob1DKO* mice) (Table 2) was constructed to study *Mob1* function in lung development (16). Doxycycline was administered in utero at E6.4 to E18.5. Alveolar hyperplasia

with reduced airspaces was found in *luMob1DKO* lungs at P0. Decreased surfactant protein expression, impaired AEC2 differentiation, unchanged *Foxa2* expression and enhanced Yap/Taz activation in *luMob1DKO* mice lungs. *In vitro* study using C22 cells with Yap/Taz knockdown and overexpression technique found Yap/Taz formed a complex with *Nkx2.1* instead of TEADs to repress expression of *Col17a1* and reduction of expression of *Col17a1* contributed to promotion of BASC cell detachment in adult lung. The lung histological alterations, decreased SPC and lethality of *luMob1DKO* (E6.5–18.5) mice were rescued in *Mob1*-deficient mutants when an additional Yap1 or Taz was mutated. Thus, the phenotypes of *luMob1DKO* (E6.5–18.5) lungs are strongly dependent on Yap/Taz.

Taz

Taz is expressed in respiratory epithelial cells of the developing lung in the mouse (17). Taz mRNA level gradually increased with advancing gestation during the lung development stages E11.5 to E18.0 tested. At E18.0, TAZ mRNA was detected primarily in the respiratory epithelium of peripheral lungs and was not detected in the conducting airways. Lung specification begins around E9.0 by detecting the earliest known marker of the lung epithelial lineage, *Nkx2.1*, which is a critical transcription factor controlling lung morphogenesis and differentiation of respiratory epithelial cells. Studies demonstrate that Taz physically interacts with *Nkx2.1* and acts as a transcriptional co-activator with *Nkx2.1* to induce the surfactant protein C (SP-C) transcription (17).

Taz knockout mice (Table 1) are viable but display abnormal alveolarization during lung development starting from P5 which causes airway enlargement, mimicking emphysema in human (11). However, the expression of *Sftpc* in mutant lungs is not significantly different from wild-type lungs. Instead, connective tissue growth factor (CTGF) was significantly reduced in Taz deficient lungs. The Taz-*Nkx2.1*-CTGF axis was proposed to be critical for lung alveolarization (18). The lung specific-Taz knockout mice are not been studied.

Yap

Yap mRNA expression is detected in mice embryonic lungs through developmental stages E10.5 to E18.5. The strongest distribution of Yap transcripts is in the epithelium of the developing airways and distal buds (14). Nuclear Yap

is co-localized with distal bud marker Sox9. Cytoplasmic Yap is co-expressed with airway marker Sox2. Nuclear Sox2 and cytoplasmic Yap co-expressed cells are committed to an airway fate during branching morphogenesis and later differentiate into specific cellular phenotypes of the conducting airways.

Unlike Taz, systematic Yap knockout led to mice lethality at E9.5 to E10.5 (10) and precluded analysis of phenotypes in the lung. To better study Yap function in lung development, Yap gene was conditionally knocked out from developing lung epithelium (YAP^{fl/fl}, Shh^{Cre/+} termed Yap^{cnull}) (Table 2) (14). The Yap^{cnull} mice were lethal at birth. Lungs from Yap^{cnull} at E12.5 were highly hypoplastic and showed severe disruption in branching morphogenesis, resulting in dilated cyst-like structures. Trachea and primary buds were grossly unaffected.

Yap nucleo-cytoplasmic compartment shift appears critical in regulating proximal-distal patterning of the lung through regulation of Sox2 expression in airway upon TGF- β -induced cues, and a decrease in YAP activity ensures epithelial cells differentiation. A model in which nuclear Yap-Tead complexes cooperate with TGF- β -induced signals to activate a transcriptional program that includes Sox2 to induce airway epithelial cell fate was proposed.

Conclusions

Homozygous deletion of *Mst1/2*, *Sav1*, *Lats2*, *Mob1* or *Yap* in mice resulted in embryonic lethality. Lung-specific knockout *Mst1/2* and *Mob1* in mice caused lung development abnormalities starting at terminal saccular stage E17.5 to P5 including increased cell proliferation, impaired lung progenitor (AEC2) cell differentiation and reduced surfactant proteins production. The lung development failure causing reduced airspaces in mutant lungs led to mice neonatal death and the mutant mice showed a phenotype mimicking RDS in preterm infants. One study demonstrated *Mst1/2* regulated lung development through *Foxa2* independently of Yap/Taz signaling (12). However, the other studies indicated that Hippo components *Mst1/2* and *Mob1* regulated lung development through Hippo effector Yap/Taz, which means a canonical Hippo-Yap signaling pathway was involved (13,15,16). Whether *Foxa2* mediates some aspects of *Mst1/2* function in the lung is unclear. The discrepancy of *Mst1/2* studies of regulatory relationship between *Mst1/2* and Yap in the lung may be due to variable efficiencies of the mouse Cre lines to remove *Mst1/2* in different mouse models (15).

However, *in vitro* studies in the same cell line MLE-12 still showed complete different results. Chung 2013 found that depletion of *Mst1/2* in MLE-12 cells decreased the level of YAP/TAZ or CTGF. In contrast, Lin 2015 found that depletion of *Mst1/2* in MLE-12 increased the level of active YAP and CTGF. It is unclear how this discrepancy has arisen and a repeat study needs to be done.

In canonical Hippo pathway, *Mst1/2* interact with *Sav1*, and *Last1/2* bind *Mob1a/b*. *Mst1-Sav1* phosphorylates and activates the *Lats1/2-Mob1a/b* complex, which in turn phosphorylates Yap and Taz to promote their cytoplasmic localization and targeting for degradation. Thus, *Mst1/2* and *Mob1a/b* may regulate YAP/TAZ in lung development through *LATS1/2* (3,4). However, a significant change of *Lats* activity in *Mst1/2* or *Mob1* lung specific knockout mice was not found. It is possible that minor changes of *LATS* activity caused by loss of *MST1/2* or *MOB1* were masked since *LATS* from the whole lung instead of purified lung epithelium was analyzed. Lung-specific knockout *Lats* mice in conjunction with double mutant (*Mst1/2* or *Mob1* mutant) analysis would shed light on the relationship between *Mst1/2*, *Lats* and Yap in the lung. These genetic studies will complement cell-based assays in delineating the interactions of Hippo pathway components in the respiratory system. Interestingly, even though complete deletion of *Sav1* in mice leads to embryonic lethality, lung-specific *Sav1* knockout mice are viable and fertile without apparent gross abnormalities (12).

In most tissues including lung, Yap plays a more role than Taz for organ development. Yap knockout mice ended up with early embryonic lethality (10). In contrast, one-fifth of Taz knockout mice grow to adulthood (11). Thus, while Taz shares functional redundancy with Yap, Yap is the major player in mediating Hippo signaling in most tissues. Lung-specific Yap knockout mice showed lung abnormalities at pseudoglandular stage starting at E12.0 which is earlier than E18.5 when lung abnormalities became obvious in *Mst1/2* and *Mob1a/1b* lung mutant mice. Yap is required for proximal-distal patterning of the lung through regulation of Sox2 expression in airway. However, in *Mst1/2*-deleted lungs, Sox2 staining was normally restricted to conducting airway epithelial cells, indicating that proximal/distal patterning of the developing lung epithelium was generally maintained when *Mst1/2* was deleted from embryonic lung. The reason for the phenotype differences between Yap mutant lungs and *Mst1/2* or *Mob1a/1b* lungs is unclear.

Respiratory diseases are a major cause of mortality

and morbidity worldwide. Characterization of the molecular pathways for lung development is important for understanding lung repair, regeneration and tumorigenesis and has an enormous potential impact on prevention and treatment of lung diseases. Even though, the function and interaction of individual Hippo pathway components in the lung development has been studied, the full spectrum of Hippo signaling effects on lung biology and pathology yet to be revealed and also the upstream regulators and downstream effectors of Hippo signaling in the lung are also largely unknown. Further elucidation of Hippo pathway upstream signals, transcriptional targets and crosstalk with other pathways will advance the understanding of lung progenitor cell behavior and improve targeted therapeutic strategies for lung diseases and cancer.

Acknowledgements

None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

- Herriges M, Morrisey EE. Lung development: orchestrating the generation and regeneration of a complex organ. *Development* 2014;141:502-13.
- Maeda Y, Davé V, Whitsett JA. Transcriptional control of lung morphogenesis. *Physiol Rev* 2007;87:219-44.
- Piccolo S, Dupont S, Cordenonsi M. The biology of YAP/TAZ: hippo signaling and beyond. *Physiol Rev* 2014;94:1287-312.
- Meng Z, Moroishi T, Guan KL. Mechanisms of Hippo pathway regulation. *Genes Dev* 2016;30:1-17.
- Zhou D, Conrad C, Xia F, et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. *Cancer Cell* 2009;16:425-38.
- Oh S, Lee D, Kim T, et al. Crucial role for Mst1 and Mst2 kinases in early embryonic development of the mouse. *Mol Cell Biol* 2009;29:6309-20.
- Lee JH, Kim TS, Yang TH, et al. A crucial role of WW45 in developing epithelial tissues in the mouse. *EMBO J* 2008;27:1231-42.
- McPherson JP, Tamblyn L, Elia A, et al. Lats2/Kpm is required for embryonic development, proliferation control and genomic integrity. *EMBO J* 2004;23:3677-88.
- Nishio M, Hamada K, Kawahara K, et al. Cancer susceptibility and embryonic lethality in Mob1a/1b double-mutant mice. *J Clin Invest* 2012;122:4505-18.
- Morin-Kensicki EM, Boone BN, Howell M, et al. Defects in yolk sac vasculogenesis, chorioallantoic fusion, and embryonic axis elongation in mice with targeted disruption of Yap65. *Mol Cell Biol* 2006;26:77-87.
- Makita R, Uchijima Y, Nishiyama K, et al. Multiple renal cysts, urinary concentration defects, and pulmonary emphysematous changes in mice lacking TAZ. *Am J Physiol Renal Physiol* 2008;294:F542-53.
- Chung C, Kim T, Kim M, et al. Hippo-Foxa2 signaling pathway plays a role in peripheral lung maturation and surfactant homeostasis. *Proc Natl Acad Sci U S A* 2013;110:7732-7.
- Lange AW, Sridharan A, Xu Y, et al. Hippo/Yap signaling controls epithelial progenitor cell proliferation and differentiation in the embryonic and adult lung. *J Mol Cell Biol* 2015;7:35-47.
- Mahoney JE, Mori M, Szymaniak AD, et al. The hippo pathway effector Yap controls patterning and differentiation of airway epithelial progenitors. *Dev Cell* 2014;30:137-50.
- Lin C, Yao E, Chuang PT. A conserved MST1/2-YAP axis mediates Hippo signaling during lung growth. *Dev Biol* 2015;403:101-13.
- Otsubo K, Goto H, Nishio M, et al. MOB1-YAP1/TAZ-NKX2.1 axis controls bronchioalveolar cell differentiation, adhesion and tumour formation. *Oncogene* 2017. [Epub ahead of print].
- Park KS, Whitsett JA, Di Palma T, et al. TAZ interacts with TTF-1 and regulates expression of surfactant protein-C. *J Biol Chem* 2004;279:17384-90.
- Mitani A, Nagase T, Fukuchi K, et al. Transcriptional coactivator with PDZ-binding motif is essential for normal alveolarization in mice. *Am J Respir Crit Care Med* 2009;180:326-38.

Cite this article as: Dai Y, Jablons D, You L. Hippo pathway in lung development. *J Thorac Dis* 2017;9(8):2246-2250. doi: 10.21037/jtd.2017.07.18